<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis -Results of a multicenter, prospective, randomized, double-blind, controlled trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-05">5 June 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Jochen</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
							<email>jochen.mainz@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrike</forename><surname>Schumacher</surname></persName>
							<email>ulrike.schumacher@med.uni-jena.de</email>
							<affiliation key="aff1">
								<orgName type="department">Institute of Medical Statistics and Documentation</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katja</forename><surname>Schädlich</surname></persName>
							<email>katja.schaedlich@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julia</forename><surname>Hentschel</surname></persName>
							<email>julia.hentschel@medizin.uniklinikum-leipzig.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">University of Leipzig Hospitals and Clinics</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christiane</forename><surname>Koitschev</surname></persName>
							<email>c.koitschev@klinikum-stuttgart.de</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Klinikum Stuttgart</orgName>
								<orgName type="department" key="dep2">Pediatric Otorhinolaryngology</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Assen</forename><surname>Koitschev</surname></persName>
							<email>a.koitschev@klinikum-stuttgart.de</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Klinikum Stuttgart</orgName>
								<orgName type="department" key="dep2">Pediatric Otorhinolaryngology</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joachim</forename><surname>Riethmüller</surname></persName>
							<email>joachim.riethmueller@med.uni-tuebingen.de</email>
							<affiliation key="aff3">
								<orgName type="department">Pediatric CF Centre</orgName>
								<orgName type="institution">Tübingen University Hospital</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Freerk</forename><surname>Prenzel</surname></persName>
							<email>freerk.prenzel@uniklinik-leipzig.de</email>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Leipzig University Hospital</orgName>
								<orgName type="institution" key="instit2">Pediatric Pneumology/Allergy</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olaf</forename><surname>Sommerburg</surname></persName>
							<email>olaf.sommerburg@med.uni-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">Pediatric CF Centre</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bärbel</forename><surname>Wiedemann</surname></persName>
							<email>baerbel.wiedemann@tu-dresden.de</email>
							<affiliation key="aff6">
								<orgName type="department">Institute for Medical Informatics and Biometry</orgName>
								<orgName type="institution">Technical University of Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Doris</forename><surname>Staab</surname></persName>
							<email>doris.staab@charite.de</email>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Charite&apos; University Hospital Berlin</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Gleiber</surname></persName>
							<email>wolfgang.gleiber@kgu.de</email>
							<affiliation key="aff8">
								<orgName type="institution">Frankfurt University Hospital</orgName>
								<address>
									<settlement>Pneumology/Allergology, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainald</forename><surname>Fischer</surname></persName>
							<email>rainald.fischer@gmail.com</email>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">München University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>München</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">James</forename><forename type="middle">F</forename><surname>Beck</surname></persName>
							<email>james.beck@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christin</forename><surname>Arnold</surname></persName>
							<email>christin.arnold@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Cooperators</surname></persName>
						</author>
						<author>
							<persName><surname>Schien</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anika</forename><surname>Nader</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">CF Centre</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Constance</forename><surname>Henn</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution" key="instit1">Leipzig University Hospital</orgName>
								<orgName type="institution" key="instit2">Pediatric Pneumology/Allergy</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christina</forename><surname>Smaczny</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Frankfurt University Hospital</orgName>
								<address>
									<settlement>Pneumology/Allergology, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudius</forename><surname>Werner</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Pediatric Pneumology</orgName>
								<orgName type="institution">Münster University Hospital</orgName>
								<address>
									<settlement>Münster</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Helge</forename><surname>Hebestreit</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Pediatric Pneumology</orgName>
								<orgName type="institution">Würzburg University Hospital</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><forename type="middle">Eberhard</forename><surname>Heuer</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">CF Center Hamburg</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sebastian</forename><surname>Schmidt</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Greifswald University Hospital</orgName>
								<address>
									<settlement>Pneumology/Allergology, Greifswald</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Corinna</forename><surname>Eichhorn</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Centre for Clinical Studies</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Isabella</forename><surname>Schiller</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Centre for Clinical Studies</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Roessler</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Centre for Clinical Studies</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ingo</forename><surname>Baumann</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Ear-Nose-Throat Department</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="laboratory">CF Centre for children and adults</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<addrLine>Kochstrasse 2</addrLine>
									<postCode>07743</postCode>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis -Results of a multicenter, prospective, randomized, double-blind, controlled trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-05">5 June 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">45C96B392223000B748F9C407E56B691</idno>
					<idno type="DOI">10.1016/j.jcf.2016.05.003</idno>
					<note type="submission">Received 19 January 2016; revised 27 April 2016; accepted 2 May 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Hypertonic saline</term>
					<term>Sodium chloride</term>
					<term>Sino-Nasal Outcome Test-20</term>
					<term>Rhinomanometry</term>
					<term>Nasal lavage</term>
					<term>Inflammation</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Chronic rhinosinusitis is a hallmark of Cystic fibrosis (CF) impairing the patients' quality of life and overall health.</s><s>However, therapeutic options have not been sufficiently evaluated.</s><s>Bronchial inhalation of mucolytic substances is a gold standard in CF therapy.</s><s>Previously,</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Cystic fibrosis (CF) is the most frequent life-shortening autosomal recessive disorder in the Caucasian population.</s><s>The impaired mucus clearance promotes infections and alters function of many organs especially of the digestive and respiratory tracts including the lower and upper airways and paranasal sinuses.</s><s>In general, CF patients exhibit both, chronic inflammation of the lower respiratory tract as well as chronic rhinosinusitis (CRS) <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>The frequency and severity of ear-nose-throat (ENT) problems are reported by only 10% of the CF patients concerned by CRS <ref type="bibr" target="#b0">[1]</ref> and are significantly underestimated by the attending physicians <ref type="bibr" target="#b3">[4]</ref>.</s><s>Indeed, almost 100% of CF patients exhibit morphological changes in computed tomography (CT) of the nose and paranasal sinuses <ref type="bibr" target="#b6">[7]</ref>.</s><s>Furthermore, it was shown, that the prevalence of rhinosinusitis is up to 63% <ref type="bibr" target="#b7">[8]</ref> and the prevalence of nasal polyps is 50% in adult CF patients <ref type="bibr" target="#b8">[9]</ref>.</s><s>Only 7.1% of CF patients are free from inflammatory changes in sinonasal histology <ref type="bibr" target="#b9">[10]</ref>.</s><s>For the lower respiratory tract, the inhalation of mucolytic and antibiotic substances is the gold standard in CF therapy.</s><s>In contrast, conventional inhalation therapy is not able to deposit relevant amounts of mucolytics or antibiotics in the paranasal sinuses <ref type="bibr" target="#b10">[11]</ref>.</s><s>Only pulsating aerosols (PARI Sinus™) facilitate a relevant deposition of nebulized drugs in the paranasal sinuses as shown by in vitro and in vivo scintigraphic studies <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>.</s><s>Previously, we performed a study with sinonasal vibrating inhalation of recombinant DNAse (dornase alfa) as a mucolytic substance.</s><s>We found that dornase alfa significantly reduces sinonasal symptoms (SNOT-20) in CF patients with CRS compared to NaCl 0.9% <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>.</s><s>Small improvements were seen with NaCl 0.9%, which did not reach significance.</s><s>By the usage of the identical study design, we aimed to assess in a next step, whether sinonasal inhalation with hypertonic saline (NaCl 6.0%) applied with vibrating aerosols reduces symptoms of rhinosinusitis in CF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Trial design</head><p><s>The study was conducted as a multicenter, prospective, randomized, double-blind, controlled, cross-over trial (Fig. <ref type="figure" target="#fig_0">1</ref>) applying the same protocol as in our previous trial on sinonasal inhalation of dornase alfa in CF patients <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>.</s><s>Patients fulfilling the study criteria were enrolled in their attending CF center and randomized to inhale either hypertonic (NaCl 6.0%) or isotonic saline (NaCl 0.9%) once daily for 28 days.</s><s>After a wash-out period of at least 28 days, patients crossed over to the alternative treatment.</s><s>Subjects were examined at the beginning (V1, V3) and the end (V2, V4) of each period.</s><s>Therapy with intravenous antibiotics within the wash-out-period delayed the start of the second period for another 28 days.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Participants</head><p><s>Participants were enrolled in eleven German CF outpatient clinics (Berlin, Frankfurt, Greifswald, Hamburg, Heidelberg, Jena, Leipzig, München, Münster, Tübingen, Würzburg).</s><s>Patients aged at least six years with a confirmed diagnosis of CF (two positive sweat tests and/or genetic analysis) and with chronic symptoms of rhinosinusitis according to the criteria of the European Position Paper on Rhinosinusitis <ref type="bibr" target="#b16">[17]</ref> were included.</s></p><p><s>Informed written consent was obtained from all patients and/ or parental guardians.</s><s>The study was approved by the local ethics committees and the Federal Institute for Drugs and Medical Devices (BfArM) and was registered at ClinicalTrials.gov</s><s>(Identifier NCT01086839) in March 2010.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Interventions and outcomes</head><p><s>Sinonasal inhalation was performed using the PARI SINUS compressor (PARI GmbH, Starnberg, Germany) together with a PARI LC SPRINT SINUS nebulizer.</s><s>NaCl 6.0% or NaCl 0.9% were aerosolized into one nostril, while the contralateral nostril was largely occluded and the soft palate elevated.</s><s>Study medication (4 mL) was administered once daily, first to one nostril for 4 min and then to the other for a further 4 min.</s><s>The total amount of study medication inhaled per session was approximately 1 mL per nostril (calculated on Total Output Rate of 220 mg/min).</s></p><p><s>From day 1 to day 28 (period 1) or day 57 to day 84 (period 2), participants nasally inhaled an ampoule NaCl 6.0% or NaCl 0.9% once daily (24 ± 2 h).</s></p><p><s>Primary outcome parameter was changes in the Sino-Nasal Outcome Test (SNOT-20, overall score).</s><s>Secondary parameters included changes in primary nasal symptoms, secondary rhinogenous parameters, general quality of life, inflammatory parameters in nasal lavage (NL), and rhinomanometry.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Sino-Nasal Outcome Test-20 (SNOT-20)</head><p><s>SNOT-20 is a disease-specific, health-related, 20-item quality of life measure for patients with rhinosinusitis focusing on rhinogenous as well as on general discomforts.</s><s>For the present study, a validated German adapted version was used.</s><s>SNOT-20 scores range between 0 and 5 for each item, with higher scores indicating a greater health burden.</s><s>The questionnaire includes four specific sections: (1) 'Total SNOT-20 score for all 20 items'; (2) 'Primary Nasal Symptoms' (PNS = nasal obstruction, sneezing, running nose, thick nasal discharge, reduced smelling); (3) 'Secondary Nasal Symptoms' (SNS = postnasal discharge, need to clear one's throat, cough, ear pressure, ear pain and facial pain/pressure) and (4) 'General Quality of Life' (GQL = dizziness, difficulty falling asleep, waking up at night, fatigue during daytime, reduced productivity, reduced concentration, frustrated/ restless/irritable, a feeling of sadness and embarrassment).</s><s>A minimum of 13 points in SNOT (excluding 'cough') was taken as inclusion criterion to facilitate a relevant improvement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5.">Nasal lavage (NL)</head><p><s>NL was performed by inserting 10 ml of sterile isotonic saline (0.9%) into each nostril with a 10 ml syringe.</s><s>This was performed in accordance with the standard diagnostic procedure for nasal lavage <ref type="bibr" target="#b17">[18]</ref>; head in a slightly reclined position and the soft palate occluded.</s><s>A protease inhibitor (Protease Inhibitor Mix G, Serva, Germany) was added to the native NL and stored at − 80 °C.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.">Immunological methods</head><p><s>Quantification of IL-1β, IL6 and IL8 in NL was done using a cytometric bead array (luminex technique): 25 μl NL were analyzed via High Sensitivity Kit (HSTCMAG-28SK-03, EMD Millipore).</s></p><p><s>Neutrophil elastase (NE) was determined using ELISA: 100 μL NL were analyzed in duplicate using the Polymorphonuclear (PMN) Elastase ELISA according to manufacturer's instructions (DEH3311, Demeditec Diagnostics GmbH).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7.">Statistical methods</head><p><s>Data were analyzed with SAS 9.3 for Windows (version 6.1.7601).</s><s>Open Clinica was used for data management (Community edition, version 3.0.4).</s><s>All variables were described via adequate non-confirmatory statistics (number of patients, mean, and standard deviation).</s><s>Values of visit 1, day 1 (period 1) and visit 3, day 57 (period 2) were used as baseline values.</s><s>For the characterization of the study population (baseline data), values of visit 1, day 1 were used.</s><s>An additional sensitivity analysis was performed to replace missing values for the primary endpoint only.</s><s>The primary and secondary endpoints were analyzed using a mixed linear model on treatment differences (NaCl 6.0% versus NaCl 0.9%) with the fixed effects`sequence of treatments´(NaCl 6.0%-NaCl 0.9% versus NaCl 0.9%-NaCl 6.0%) and 'period' (period 1 versus 2) and as random effect the patient nested in sequence (intention-to-treat-analysis).</s><s>The significance level was set at alpha = 0.05 (95% confidence intervals are shown).</s><s>An additional post-hoc analysis (t-test, Bonferroni correction (factor 5, alpha = 0.01)) was done to consider treatment effects in SNOT total score and subscores separately for every treatment dose (alpha = 0.01).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head><p><s>A total of 69 patients were enrolled between April 2010 and June 2013 (first subject in: 27/04/2010, last subject out: 05/06/ 2013).</s><s>Fig. <ref type="figure">2</ref> illustrates the study process including the number of participants who were randomly assigned, who received one of the two sequences, who dropped out (with reasons), and who were analyzed for the primary outcome.</s><s>Tables <ref type="table" target="#tab_1">1 and 2</ref> summarize baseline data as well as the clinical characteristics of participants and findings in each of the study arms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Primary outcome analysis</head><p><s>Patients treated with NaCl 6.0% showed a significant improvement in total SNOT score of 3.1 ± 6. showed significant treatment effects for both concentrations of saline.</s><s>The analysis of the cross over design showed no significant sequence (F 1.65 = 0.56, p-value 0.46) or period effects (F 1.51 = 2.90, p = 0.095).</s><s>Fig. <ref type="figure">3</ref> demonstrates the changes in all SNOT-20 items after 28 days of sinonasal inhalation with either NaCl 0.9% or NaCl 6.0%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Secondary endpoints</head><p><s>PNS scores improved by 4.2 ± 13.6 points from day 1 to day 29 in patients treated with NaCl 6.0% (34.7 ± 14.1 to 31.9 ± 15.8).</s><s>When treated with NaCl 0.9% an improvement of the PNS score from day 1 (36.5 ± 15.0) to day 29 (29.4 ± 15.9) of 7.0 ± 14.3 points was shown.</s><s>The difference between the two treatments is not significant (F 1.51 = 1.41p = 0.24).</s><s>The analysis of the cross-over design did not show significant sequence (F 1.65 = 2.43, p = 0.12) or period effects (F 1,51 = 0.71, p = 0.40).</s><s>Patients treated with NaCl 6.0% showed an improvement in SRS scores from day 1 (22.8 ± 12.1) to day 29 (21.0 ± 13.6) of 2.7 ± 9.8 points.</s><s>When treated with NaCl 0.9%, SRS scores improved by 3.4 ± 10.4 points from day 1 (24.9 ± 13.8) to day 29 (21.2 ± 12.9).</s><s>The difference between the two treatments is not significant (F 1.51 = 0.08, p = 0.78).</s><s>Patients treated with NaCl 6.0% showed an improvement of the GQL scores from day 1 (16.7 ± 13.4) to day 29 (14.3 ± 11.8) of 2.8 ± 8.8 points.</s><s>When treated with NaCl 0.9% an improvement of the GQL score from day 1 (18.2 ± 13.8) to day 29 (12.7 ± 11.1) of 5.1 ± 9.9 points was shown.</s><s>The difference between the two treatments is not significant (F 1.51 = 1.75, p = 0.19).</s><s>The analysis of the cross over design revealed no sequence-(F 1.65 = 0.02, p = 0.88) but a significant period effect (F 1.51 = 6.7, p = 0.013).</s><s>Patients treated with either NaCl 6.0% or NaCl 0.9% showed a slight improvement of nasal airflow (inspiratory flow before decongestion) from day 1 to day 29.</s></p><p><s>Composite scores in each treatment arm are shown graphically in Fig. <ref type="figure">4</ref>.</s></p><p><s>In both treatment groups, no significant changes of inflammatory parameters (NE, IL1β, IL6, and IL8) in NL from day 1 to day 29 were observed, although means of IL1ß and IL8 appeared to be somewhat lower after 28 days of sinonasal inhalation with hypertonic saline (Fig. <ref type="figure" target="#fig_2">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Safety</head><p><s>Altogether, sinonasal inhalation of hypertonic and isotonic saline was well tolerated.</s><s>Safety reports from 59 patients documented a total of 253 adverse events.</s><s>Ten of the adverse events were classified as serious (three pulmonary exacerbations, diabetic imbalance, oesophageal varices bleeding, portal vein thrombosis, intravenous antibiotic therapy, viral gastroenteritis, thorax pain, port catheter implantation).</s><s>Thirteen events were probably or very likely related to the interventions and a total of 86 events were considered to be possibly or doubtfully related.</s><s>Adverse events classified as probable (NaCl 0.9%: N = 4, NaCl 6.0%: N = 3, washout: N = 1) or very likely (NaCl 0.9%: N = 5, NaCl 6.0%: N = 0, washout: N = 0) related to study medication were epistaxis, otalgia, pain during inhalation and pressure/burning pain in sinonasal segment.</s><s>The remaining 167 events were not related to the study medication.</s><s>Adverse events occurred almost equally in both treatment groups (NaCl 0.9%: N = 80, NaCl 6.0%: N = 74, washout/before start/ after end: N = 99).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>This multicenter, prospective, randomized, double-blind, controlled trial was performed to assess the effects of hypertonic saline (NaCl 6.0%) vs. isotonic saline (NaCl 0.9%) inhaled as vibrating aerosol on sinonasal symptoms in CF patients suffering from CRS. CRS in CF is caused by impaired mucociliary clearance in the upper airway segment due to an enhanced viscosity of secretions.</s><s>Hypertonic saline is a standard therapy for CF-related pulmonary involvement -based on the (1) reduction of viscosity and elasticity by a breakdown of ionic bonds of mucus, (2) rehydrating of secretions due to an increased osmotic flow of water into the mucus layer and (3) enhanced mucus clearance by building more compact mucin macromolecules <ref type="bibr" target="#b19">[19]</ref>.</s><s>As a principal result of the study, both concentrations of saline improved symptoms assessed with the well-established Sino-Nasal Outcome Test-20 (SNOT-20).</s><s>These effects were more obvious after 28 days of sinonasal inhalation with NaCl 0.9%.</s><s>Isotonic saline improved SNOT total score by − 5.1 points while hypertonic saline only led to − 3.1 points of improvement.</s><s>Thereby, changes in SNOT total scores ≥ 5 points are considered as clinically relevant.</s><s>This study shows that NaCl 6.0% is not superior to NaCl 0.9% regarding the treatment of sinonasal symptoms.</s></p><p><s>In our preceding trial, dornase alfa caused statistically and clinically benefits in CF patients with CRS: it improved total SNOT score by − 7.1 points whereas isotonic saline improved symptoms by − 1.3 points (difference: 5.9 points) <ref type="bibr" target="#b14">[15]</ref>.</s><s>Compared to the present study, the effects of hypertonic saline on sinonasal symptoms are much weaker than those of dornase alfa.</s><s>We attribute this finding to the irritating properties of hypertonic saline on airway mucosa, which are well described in trials assessing bronchial inhalation with hypertonic saline <ref type="bibr" target="#b20">[20,</ref><ref type="bibr" target="#b21">21]</ref> where saline in concentrations from 6 to 7% provoked cough and airway obstructions.</s><s>Fig. <ref type="figure">3</ref>. Changes to SNOT-20 items after 28 days of sinonasal inhalation with either isotonic (NaCl 0.9%) or hypertonic (NaCl 6.0%) saline.</s><s>Fig. <ref type="figure">4</ref>. Effects of sinonasal inhalation of hypertonic saline (NaCl 6.0%) and isotonic saline (NaCl 0.9%) on SNOT-20 subscores.</s><s>(Sino-Nasal Outcome Test (SNOT-20): total score represents the sum of all 20 items.</s><s>PNS (primary nasal symptoms) subscore includes nasal obstruction, sneezing, running nose, thick nasal discharge, reduced smelling.</s><s>(SNS (secondary nasal symptoms) subscore includes postnasal discharge, need to clear one's throat, cough, ear pressure, ear pain and facial pain/pressure.</s><s>GQL (general quality of life) subscore includes dizziness, difficulty falling asleep, waking up at night, fatigue during daytime, reduced productivity, reduced concentration, frustrated/restless/irritable, a feeling of sadness and embarrassment).</s><s>The boxes extend from the 25th to 75th percentiles, the line in the middle of the box is the median, the whiskers go down to the 10th percentile/up to the 90th and points above the whiskers are outliers (alpha = 0.05).</s><s>group (NaCl 0.9%) <ref type="bibr" target="#b21">[21]</ref>.</s><s>Nevertheless, due to improved lung function and reduced exacerbation rates, the authors concluded that 'hypertonic saline, preceded by a bronchodilator, is an inexpensive, safe, and effective additional therapy for patients with cystic fibrosis'.</s><s>In the present study, adverse events classified as probable (NaCl 0.9%: N = 4, NaCl 6.0%: N = 3, washout: N = 1) or very likely (NaCl 0.9%: N = 5, NaCl 6.0%: N = 0, washout: N = 0) related to study medication were epistaxis, otalgia, pain during inhalation and pressure in sinonasal segment.</s><s>Hence, one can derive from the adverse events that isotonic saline also exhibits irritant and pro-algesic properties in the UAW.</s><s>Therefore, we must assume that SNOT-20 may have limitations to assess sinonasal symptoms on the basis of our study design <ref type="bibr" target="#b22">[22,</ref><ref type="bibr" target="#b23">23]</ref>.</s><s>To some extent the result of the primary outcome parameter was surprising: After the close-out of the study, many patients reported a very effective mobilization of mucus and crusts from the UAW segment for the study period in which they received hypertonic saline.</s><s>Thereby, therapeutic effect of mucolytic might not be adequately reflected in the subjective perception of SNOT-20 scores.</s><s>Objective measures like `quantification of mobilized amounts of mucus´would have been a particularly interesting outcome parameter.</s><s>However, most of the secretions mobilized from the nose and paranasal sinuses drain physiologically as postnasal drip <ref type="bibr" target="#b24">[24]</ref> and are swallowed, or to a much lower proportion expectorated, after reaching the pharynx.</s><s>Therefore, quantification and comparison of secretions drained from the UAW appears to be almost impossible in a clinical trial involving CF patients.</s><s>Two reasons prompted us to choose the SNOT-20 as the primary outcome parameter: first, the score -which is widely used for evaluation of conservative and surgical interventions in patients with rhinosinusitiswas successfully applied in our preceding trials applying dornase alfa and tobramycin to paranasal sinuses with the same vibrating nebulizer <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b25">25]</ref>.</s><s>Secondly, serial MR-Imaging of sinonasal ventilated spaces as an alternative would have been interesting but costs to perform four sinonasal MRI in each of the 69 patients (276 MRI scans) by far exceeded our financial means.</s></p><p><s>As a second outcome parameter nasal patency was examined via active anterior rhinomanometry in a subgroup of patients.</s><s>This technique allows the measurement of the inspiratory and expiratory flow and resistance of the nose.</s><s>Sinonasal therapy might increase nasal patency by reducing mucosal swelling and by a higher fluidity of nasal secretions and mobilization of crusts.</s><s>Patients treated with either NaCl 6.0% or NaCl 0.9% showed small improvements of nasal airflow, whereas NaCl 0.9% seemed to be slightly more effective without reaching statistical significance in comparison to hypertonic saline.</s><s>Indeed, there was no need and no potential for improving nasal patency since mean total nasal inspiratory flow was within the normal range.</s><s>To acquire data on mucosal swelling, polyps, and secretions, imaging techniques such as computed tomography or the more expensive but radiation free magnetic resonance tomography would be required.</s><s>The latter radiation-free method is quite interesting for longitudinal studies on ventilation of UAW.</s></p><p><s>Furthermore, no alterations of inflammatory parameters (NE, IL1β, IL6, and IL8) in NL were observed.</s><s>Previously it had been shown that hyperosmolar environments induce a histamine release from mast cells and basophils in vitro and inflammatory mediators (histamine, TAME esterase, immunoreactive leukotriene) in vivo <ref type="bibr" target="#b26">[26]</ref>.</s><s>Additionally, van der Vaart et al. demonstrated in a study including 16 healthy intermittent smokers that repeated sputum inductions with hypertonic saline (NaCl 4.5%) induced/provoked a neutrophilic and a prolonged eosinophilic inflammatory response -IL8 increased significantly as well <ref type="bibr" target="#b27">[27]</ref>.</s><s>Gräber et al. investigated the effects of hypertonic saline on airway inflammation in a betaENaC-overexpressing mouse model for chronic obstructive lung disease and found that inhalation of hypertonic saline triggers proinflammatory stress (osmotic stress response) which may limit the therapeutic benefits of the treatment and require an adjunct anti-inflammatory strategy.</s><s>For sinonasal inhalation, the results of cytokine analysis did not indicate proinflammtory effects of hypertonic saline <ref type="bibr" target="#b28">[28]</ref>.</s><s>In conclusion, a study on CRS in CF comparing dornase alfa, isotonic and hypertonic saline at concentration 3 and 6% with an imagine technique as main outcome parameter would be very interesting.</s><s>For clinical practice we can conclude, that sinonasal inhalation of both isoand hypertonic saline is a safe adjunct therapy for CF patients with CRS.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Design of the study (Random = randomization, V = visit, min = minimum).</s></p></div></figDesc><graphic coords="3,141.85,69.11,321.58,163.79" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Fig. 2. Participant flow diagram.</s></p></div></figDesc><graphic coords="4,93.54,263.57,398.56,469.02" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5. Changes in cytokines in nasal lavage after 28 days of sinonasal inhalation with either isotonic (NaCl 0.9%) or hypertonic (NaCl 6.0%) saline (given as interquartile range with median, n = 27-30, NE: neutrophil elastase, IL: interleukin).</s></p></div></figDesc><graphic coords="8,106.87,69.11,371.92,273.83" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="7,132.78,389.37,339.53,295.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Demographic and clinical characteristics of study participants.</s></p></div></figDesc><table><row><cell>Total</cell><cell>NaCl 0.9%-NaCl 6.0%</cell><cell>NaCl 6.0%-NaCl 0.9%</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Summary of findings.Hypertonic saline (NaCl 6.0%) compared to isotonic saline (NaCl 0.9%) with vibrating aerosol inhalation Patients: CF patients with chronic rhinosinusitis Settings: Multicenter, prospective, randomized, double-blind, controlled trial (12 German Cystic Fibrosis outpatient clinics)</s></p></div></figDesc><table><row><cell>Intervention: NaCl 6.0%</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Comparison: NaCl 0.9%</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Outcome</cell><cell>NaCl 6.0% (CI 95%)</cell><cell>Numbers analyzed</cell><cell>NaCl 0.9% (CI 95%)</cell><cell>Numbers analyzed</cell></row><row><cell>SNOT total score:</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (Pt)</cell><cell>23.0 ± 10.4 (20.3-25.7)</cell><cell>59</cell><cell>24.8 ± 11.0 (22.0-27.5)</cell><cell>65</cell></row><row><cell>Day 29 (Pt)</cell><cell>20.7 ± 10.1 (18.1-23.3) a</cell><cell>62</cell><cell>19.4 ± 9.6 (17.0-21.8) a</cell><cell>65</cell></row><row><cell>Change(Pt)</cell><cell>− 3.1 ± 6.5</cell><cell></cell><cell>− 5.1 ± 8.3</cell><cell></cell></row><row><cell>PNS score:</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (Pt)</cell><cell>34.7 ± 14.1(31.0-38.4)</cell><cell>59</cell><cell>36.5 ± 15.0 (32.8-40.2)</cell><cell>65</cell></row><row><cell>Day 29 (Pt)</cell><cell>31.9 ± 15.8 (27.9-35.9)</cell><cell>62</cell><cell>29.4 ± 15.9 (25.4-33.3) a</cell><cell>65</cell></row><row><cell>Change (Pt)</cell><cell>− 4.2 ± 13.6</cell><cell></cell><cell>− 7.0 ± 14.3</cell><cell></cell></row><row><cell>SRS score:</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (Pt)</cell><cell>22.8 ± 12.1 (19.6-25.9)</cell><cell>59</cell><cell>24.9 ± 13.8 (21.4-28.3)</cell><cell>65</cell></row><row><cell>Day 29 (Pt)</cell><cell>21.0 ± 13.6 (17.6-24.5)</cell><cell>62</cell><cell>21.2 ± 12.9 (18.0-24.4)</cell><cell>65</cell></row><row><cell>Change (Pt)</cell><cell>− 2.7 ± 9.8</cell><cell></cell><cell>− 3.4 ± 10.4</cell><cell></cell></row><row><cell>GQL score:</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (Pt)</cell><cell>16.7 ± 13.4 (13.2-20.2)</cell><cell>59</cell><cell>18.2 ± 13.8 (14.8-21.6)</cell><cell>65</cell></row><row><cell>Day 29 (Pt)</cell><cell>14.3 ± 11.8 (11.3-17.3)</cell><cell>62</cell><cell>12.7 ± 11.1 (10.0-15.5) a</cell><cell>65</cell></row><row><cell>Change (Pt)</cell><cell>− 2.8 ± 8.8</cell><cell></cell><cell>− 5.1 ± 9.9</cell><cell></cell></row><row><cell>FEV 1:</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (%)</cell><cell>84.4 ± 22.7 (78.6-90.1)</cell><cell>62</cell><cell>82.0 ± 23.1 (76.1-87.8)</cell><cell>63</cell></row><row><cell>Day 29 (%)</cell><cell>84.4 ± 22.5 (78.6-90.2)</cell><cell>60</cell><cell>82.7 ± 23.2 (76.9-88.6)</cell><cell>63</cell></row><row><cell>Change (%)</cell><cell>0.04 ± 6.73</cell><cell></cell><cell>− 0.3 ± 6.9</cell><cell></cell></row><row><cell>Rhinomanometry:</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">∑Insp. flow before decongestion</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (mL/s)</cell><cell>706.7 ± 349.1 (590.3-823.1)</cell><cell>37</cell><cell>694.8 ± 362.9 (568.2-821.4)</cell><cell>34</cell></row><row><cell>Day 29 (mL/s)</cell><cell>788.5 ± 334.5 (665.8-911.2)</cell><cell>31</cell><cell>812.1 ± 355.0 (686.2-938.0)</cell><cell>33</cell></row><row><cell>Change (%)</cell><cell>11.6</cell><cell></cell><cell>16.9</cell><cell></cell></row><row><cell cols="2">∑Insp. flow after decongestion</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Day 1 (mL/s)</cell><cell>1563.4 ± 988.1 (1207.2-1919.7)</cell><cell>32</cell><cell>1404.1 ± 890.5 (1058.8-1749.4)</cell><cell>28</cell></row><row><cell>Day 29 (mL/s)</cell><cell>1665.3 ± 1122.4 (1230.1-2100.6)</cell><cell>28</cell><cell>1763.8 ± 1116.0 (1354.4-2173.1)</cell><cell>31</cell></row><row><cell>Change (%)</cell><cell>6.5</cell><cell></cell><cell>25.6</cell><cell></cell></row><row><cell cols="2">Values are given as mean ± standard deviation.</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CF: Cystic Fibrosis.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CI: confidence interval.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">SNOT: Sino-Nasal Outcome Test.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">PNS: primary nasal symptoms.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">SRS: secondary rhinogenous symptoms.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">GQL: general quality of life.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">∑Insp. flow: sum of inspiratory flow of both nostrils.</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pt: POINTS.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NL: nasal lavage.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a Significantly different in comparison to day 1 (post-hoc analysis, α b 0.01).</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J.G. Mainz et al. / Journal of Cystic Fibrosis 15 (2016) e57-e66</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We kindly acknowledge all study participants, the study team including all study nurses and physicians involved.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>The study was supported by a financial grant from "Association Luxembourgeoise de Lutte contre la Mucoviscidose a.s.b.l." (ALM) in co-operation with Mukoviszidose Institut gGmbH, Bonn, the research and development arm of German Cystic Fibrosis Association Mukoviszidose e.V (grant number: S03/09).</s></p><p><s>The PARI GmbH provided the study centers with nebulizers and blinded medication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>All authors confirm that they are not involved in any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Contributors</head><p><s>Principal investigator: JGM.</s><s>Design and realization of study: JGM, KS, JH, CK, AK, JR, FP, OS, BW, DS, WG, RF, JFB.</s><s>Performed the experiments: JH, CA.</s><s>Analyzed the data: JGM, US, JH, CA.</s><s>Wrote the paper: JGM, CA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval</head><p><s>The trial was approved by the local Ethics Committee (vote number: 2720-12/09).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Registration</head><p><s>The trial has been registered at ClinicalTrials.gov.</s><s>(Identifier NCT01086839) in March 2010.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient consent</head><p><s>Obtained.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Upper respiratory disease, sinusitis, and polyposis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">V</forename><surname>King</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rev Allergy</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="143" to="157" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Muhlebach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Wedd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Drake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Leigh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Pulmonol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="445" to="451" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">V</forename><surname>King</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="566" to="572" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Management of chronic rhinosinusitis in CF</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koitschev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cyst Fibros</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">S1</biblScope>
			<biblScope unit="page" from="10" to="14" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Aanaes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cyst Fibros</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">S2</biblScope>
			<biblScope unit="page" from="1" to="20" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Sinus disease in cystic fibrosis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Henig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rev Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="51" to="63" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">CT characterization of inflammatory paranasal sinus disease in cystic fibrosis</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Eggesbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sovik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dolvik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kolmannskog</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Radiol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="21" to="28" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Berkhout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Van Rooden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rijntjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Fokkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>El Bouazzaoui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Heijerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cyst Fibros</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="442" to="448" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Prevalence and histopathology of chronic polypoid sinusitis in pediatric patients with cystic fibrosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Schraven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wehrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Blumenstock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koitschev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cyst Fibros</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="181" to="186" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Rhinosinusitis in cystic fibrosis: not a simple story</title>
		<author>
			<persName><forename type="first">D</forename><surname>Babinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trawinska-Bartnicka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Pediatr Otorhinolaryngol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="619" to="624" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Deposition of aerosolized particles in the maxillary sinuses before and after endoscopic sinus surgery</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>St Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Hitzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Wiedmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Rimell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Rhinol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="196" to="197" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Nasally inhaled pulsating aerosols: lung, sinus and nose deposition</title>
		<author>
			<persName><forename type="first">W</forename><surname>Möller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Saba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haussinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schuschnig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rhinology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="286" to="291" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Pulsating aerosols for drug delivery to the sinuses in healthy volunteers</title>
		<author>
			<persName><forename type="first">W</forename><surname>Möller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schuschnig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Khadem</forename><surname>Saba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Junge-Hulsing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="382" to="388" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Ventilation and drug delivery to the paranasal sinuses: studies in a nasal cast using pulsating airflow</title>
		<author>
			<persName><forename type="first">W</forename><surname>Möller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schuschnig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mentzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Keller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rhinology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="213" to="220" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled crossover trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schädlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koitschev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Koitschev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cyst Fibros</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="461" to="470" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Sinonasal inhalation of dornase alfa in CF: a double-blind placebocontrolled cross-over pilot trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ritschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Mentzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Riethmüller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koitschev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Auris Nasus Larynx</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="220" to="227" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Fokkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mullol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Alobid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baroody</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rhinology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Influences of nasal lavage collection-, processing-and storage methods on inflammatory markers-evaluation of a method for non-invasive sampling of epithelial lining fluid in cystic fibrosis and other respiratory diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hentschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Doht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Böer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sonnemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">404</biblScope>
			<biblScope unit="page" from="41" to="51" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Cystic Fibrosis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="e57" to="e66" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Nebulised hypertonic saline for cystic fibrosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Mcdonald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">D001506</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Mucus clearance and lung function in cystic fibrosis with hypertonic saline</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Donaldson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Zeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Knowles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tarran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Boucher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="241" to="250" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Elkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Harbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Moriarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Marks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="229" to="240" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Impact of gender, age, and comorbidities on quality of life in patients with chronic rhinosinusitis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Blumenstock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Zalaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Praetorius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Klingmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sittel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rhinology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="268" to="272" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Psychometric and clinimetric validity of the 20-item Sino-Nasal Outcome Test (SNOT-20)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Piccirillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Merritt</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Richards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="41" to="47" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Sinonasal mucociliary clearance in health and disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Otol Rhinol Laryngol Suppl</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page" from="20" to="26" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schädlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Michl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schelhorn-Neise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koitschev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Des Devel Ther</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="209" to="217" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">In vivo release of inflammatory mediators by hyperosmolar solutions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Silber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Proud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Warner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Naclerio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kagey-Sobotka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lichtenstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Rev Respir Dis</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="606" to="612" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Ten Hacken NH. Repeated sputum inductions induce a transient neutrophilic and eosinophilic response</title>
		<author>
			<persName><forename type="first">H</forename><surname>Van Der Vaart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Postma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Timens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Kauffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Hylkema</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1157" to="1164" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Gräber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhou-Suckow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schatterny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Mall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Cell Mol Biol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="410" to="417" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mainz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Cystic Fibrosis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="e57" to="e66" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
